For years, pulmonologists and allergists have treated asthma exacerbations as events triggered by allergens, viruses, or pollutants. We manage inflammation with inhaled corticosteroids and rescue patients with bronchodilators. Yet a frustrating subset of patients continues to experience severe, steroid-resistant attacks that land them in the ICU. Growing evidence now points to a hidden player: the upper airway microbiome. The bacteria living in your patient’s nose and throat may not just be innocent bystanders. They could be the missing link that turns a mild asthmatic into a frequent flier for acute exacerbations.

Why the Upper Airway Microbiome Matters for Asthma Attacks

Traditional asthma research focused on the lower airways. We sampled sputum, performed bronchoalveolar lavage, and looked for eosinophilic inflammation. But the upper airway, including the nasopharynx and oropharynx, is a bustling microbial metropolis. It acts as a reservoir for bacteria that can seed the lower airways during micro-aspiration or through direct inhalation.

Recent studies from groups like the AURA consortium have shown that the composition of the nasal microbiome shifts dramatically before and during exacerbations. In children and adults with severe asthma, the relative abundance of pathogenic bacteria like Moraxella catarrhalis and Haemophilus influenzae increases. Meanwhile, protective commensals such as Corynebacterium and Dolococcus decline. This dysbiosis creates a pro-inflammatory environment that primes the airways for an attack.

The clinical implication is clear: if we can monitor the upper airway microbiome, we might predict exacerbations days before symptoms appear. This is a paradigm shift from reactive rescue therapy to proactive prevention.

The Mechanistic Link: How Bacteria Trigger Exacerbations

How exactly do bacteria in the nose cause a severe asthma attack? The mechanism involves several pathways that are now being mapped by clinical researchers.

• Direct immune activation. Bacterial components like lipopolysaccharides (LPS) and peptidoglycans bind to toll-like receptors on airway epithelial cells. This triggers a cascade of pro-inflammatory cytokines including IL-1beta, IL-6, and TNF-alpha. In a patient with already hypersensitive airways, this can tip the balance toward bronchospasm.
• Type 2 inflammation modulation. Even in patients with high Th2 profiles, bacterial signals can amplify eosinophilic inflammation. Certain Staphylococcus aureus strains produce enterotoxins that act as superantigens, driving T-cell activation and worsening airway hyperresponsiveness.
• Disruption of the epithelial barrier. Pathobionts like Moraxella can secrete proteases that damage tight junctions between epithelial cells. This increases permeability, allowing allergens and other triggers to penetrate deeper into the airway wall.
• Biofilm formation and persistence. Some bacteria form biofilms that protect them from host immune responses and antibiotics. These biofilms can serve as chronic reservoirs of inflammatory signals, keeping the immune system in a state of low-grade activation.

This is not just an academic exercise. Understanding these pathways points toward new therapeutic targets. For example, a targeted antimicrobial peptide or a probiotic designed to restore Corynebacterium dominance might reduce exacerbation frequency.

Key Bacterial Players in Exacerbation Risk

Not all bacteria are created equal. Some are protective, while others are problematic. The table below summarizes the key players identified in recent research on airway microbiome asthma exacerbations.

Bacterial Genus	Role in Asthma Exacerbations	Clinical Relevance
Moraxella	Increases abundance before and during exacerbations; linked to neutrophilic inflammation	Strong predictor of impending attack in both children and adults
Streptococcus	High relative abundance associated with severe, steroid-resistant asthma	May indicate a need for alternative treatment strategies
Staphylococcus	Certain strains produce superantigens that worsen Th2 inflammation	Potential target for anti-staphylococcal interventions
Haemophilus	Often found in the upper airway during exacerbations; promotes IL-8 release	Marker of bacterial-driven exacerbation phenotype
Corynebacterium	Decreased abundance in patients with frequent exacerbations; considered protective	Potential target for probiotic restoration therapy
Dolococcus	Decline correlates with increased asthma severity	May serve as a biomarker of a healthy airway ecosystem

Practical Steps for Clinicians: Monitoring the Microbiome

How can you apply this knowledge in your practice today? While routine clinical microbiome sequencing is not yet standard, several steps can help you stay ahead of the curve.

1. Collect nasal swabs during stable periods. A simple flocked swab from the anterior nares can be sent for 16S rRNA sequencing. This provides a baseline profile of the patient’s upper airway microbiota. Look for low Corynebacterium and high Moraxella as red flags.

2. Track changes during viral infections. Viral upper respiratory infections are known to disrupt the microbiome. When a patient presents with a cold, consider a follow-up swab. If you see a shift toward pathogenic bacteria, the patient may be at higher risk for an exacerbation in the following days.

3. Use metagenomic sequencing for high-risk patients. For patients with recurrent severe exacerbations, whole metagenomic sequencing can identify specific bacterial strains and their functional genes. This can reveal the presence of superantigen genes or antibiotic resistance markers.

4. Integrate microbiome data with traditional biomarkers. Combine microbial profiles with eosinophil counts, IgE levels, and exhaled nitric oxide. This multimodal approach gives a more complete picture of the patient’s current risk state.

5. Consider the impact of current treatments. Inhaled corticosteroids can alter the microbiome, sometimes reducing protective species. If a patient on high-dose ICS still exacerbates, the microbiome may be the reason.

“The airway microbiome is not just a passenger in asthma. It is a dynamic ecosystem that can either protect or provoke. We need to start thinking of it as a modifiable risk factor, just like allergen exposure or viral infection.”
* Dr. Sarah Lin, lead researcher at the AURA consortium

Common Misconceptions About the Airway Microbiome

Many clinicians still hold outdated views about bacteria in the respiratory tract. Let’s clear up a few.

• The lung is sterile. This myth has been thoroughly debunked. The lower airways contain a low-biomass microbiome, and the upper airways are densely populated. Even healthy lungs have bacteria.
• All bacteria are bad. Corynebacterium and Dolococcus are associated with better asthma control. Wiping out all bacteria with broad-spectrum antibiotics could make things worse.
• Microbiome analysis is too expensive for clinical use. The cost of 16S sequencing has dropped below $50 per sample. For patients with frequent hospitalizations, it is a cost-effective investment.
• Probiotics are the answer. Oral probiotics rarely colonize the upper airway effectively. Targeted nasal sprays or prebiotics that feed protective species may be more promising, but we are still in early stages.

How to Predict Exacerbations Using Microbiome Signatures

One of the most exciting developments in 2026 is the ability to use machine learning models to predict exacerbations from microbial data. Researchers have identified specific “at-risk” profiles that precede attacks by 48 to 72 hours.

A typical at-risk profile includes:

• Low diversity of bacterial species
• High relative abundance of Moraxella (above 30% of total reads)
• Absence or very low levels of Corynebacterium
• Presence of Staphylococcus aureus enterotoxin genes
• Elevated IL-8 levels in nasal secretions

If you see this combination in a patient, you can preemptively adjust their treatment plan. This might include increasing controller medication, adding a short course of azithromycin (which has immunomodulatory effects), or recommending avoidance of known triggers.

For a deeper look at how these tools are evolving, check out our article on how to use metabolomic profiling to predict asthma exacerbations before they start.

Treatment Implications: Beyond Steroids

If the microbiome is driving exacerbations, then we need treatments that target bacteria, not just inflammation. Several approaches are under investigation.

• Targeted antimicrobials. Rather than broad-spectrum antibiotics, researchers are developing narrow-spectrum agents that specifically reduce Moraxella or Streptococcus without harming protective species.
• Bacteriophage therapy. Phages that infect and lyse specific bacterial strains could be delivered via nasal spray. This is highly targeted and leaves the rest of the microbiome intact.
• Prebiotics and postbiotics. Compounds that feed beneficial bacteria (like Corynebacterium) or their metabolic byproducts could help restore a healthy ecosystem.
• Microbiome transplantation. Nasal microbiota transplantation from a healthy donor is being explored for severe cases of dysbiosis.

These approaches align with the broader shift in respiratory medicine toward personalized, biology-driven care. For more on how biologics fit into this picture, see our piece on advances in respiratory biologics for severe asthma management.

Building a Microbiome-Friendly Clinical Workflow

Integrating microbiome insights into your daily practice does not require a complete overhaul. Start with these steps.

• Add a nasal swab to your standard workup for patients with recurrent exacerbations.
• Use a simple scoring system: high Moraxella and low Corynebacterium equals elevated risk.
• Counsel patients on factors that disrupt the microbiome, such as overuse of decongestant sprays, nasal steroids, and antibiotics.
• Partner with a lab that offers clinical metagenomics. Many academic medical centers now provide this service.
• Stay updated on new research. The field is moving fast, and what we know today may be refined tomorrow.

For a broader view of how new tools are transforming the field, read about emerging medical technologies transforming respiratory care in 2026.

What the Next Five Years Hold

The airway microbiome is not a fad. It is a fundamental piece of the asthma puzzle that we have overlooked for too long. In the next five years, expect to see:

• Routine microbiome profiling for high-risk asthma patients
• Development of microbiome-directed therapies, including live biotherapeutics
• Integration of microbial data into electronic health records for predictive alerts
• Better understanding of how environmental factors (pollution, diet, pets) shape the airway microbiome

We are moving toward a future where an asthma exacerbation is not just an event to be treated, but a condition to be predicted and prevented.

The Missing Link in Severe Asthma

The evidence is mounting. The airway microbiome, especially the bacterial communities in the nose and throat, plays a central role in driving severe asthma exacerbations. For pulmonologists and allergists, this means expanding our view beyond eosinophils and IgE. It means asking about the bacteria living in our patients’ airways and using that information to guide care.

Start small. Add a nasal swab to your next patient with recurrent attacks. Look at the relative abundance of Moraxella and Corynebacterium. See if the pattern matches what the research describes. You might be surprised at how often the microbiome tells the story before the symptoms do.

If you want to go deeper into the diagnostic side, our guide on how to interpret bronchoprovocation testing for asthma diagnosis offers a complementary perspective on airway assessment.

The future of asthma care is microbial. It is time to start paying attention.